Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), has officially announced the launch of several new enhancements across its data and software solutions, each one geared towards enhancing real-world insights and expediting treatment options in ophthalmology.
According to certain reports, the stated assortment of enhancements, for starters, include integration between Site Explorer and Verana Trial Connect.
This translates to how Site Explorer , an intuitive tool to help sponsors and contract research organizations (CROs) make data-driven site selections, can now harness the prowess of Verana Trial Connect (VTC) to leverage Electronic Health Record (EHR) data and help practices identify eligible trial patients easier, faster, and in greater numbers. As for the result, this combined solution should be able to offer enhanced sponsor reporting.
Next up, we have new variables coming into play for Qdata. These variables basically include corneal staining for Dry Eye Disease and diplopia for Thyroid Eye Disease, each one arriving as fit-for-purpose modules that bank upon RWD from the IRIS Registry to provide a comprehensive view of the patient journey.
“At Verana Health, we are dedicated to providing innovative technology and data-driven solutions for advancing ophthalmic research and patient care,” said Sujay Jadhav, CEO of Verana Health. “We’re proud to introduce a series of advances that will help life sciences companies and clinicians improve research operations and patient outcomes.”
Another detail worth a mention is rooted in the availability of expanded MIPS advisory services that include coaching and advisory options so to help ophthalmology practices maximize their incentive payment potential, while simultaneously reducing their compliance burden and audit risk exposure.
For better understanding, MIPS Advisory Services ensure that practices stay compliant with MIPS reporting requirements and frequent regulatory changes.
Among other things, it ought to be acknowledged how Verana Health will present a range of new enhanced product, services, and research during the AAO 2025 Annual Meeting on October 18-20.
This presentation, on its part, is likely to include an overview of MIPS Advisory Services for ophthalmologists and their teams. Alongside that, jointly conducted research, facilitated through collaborative efforts of Verana Health and Stanford University, will be available on demand.
Named as “Using natural language processing to identify and characterize patients with thyroid eye disease in the IRIS Registry”, the study in question examines real value of analyzing unstructured EHR data in the IRIS Registry.
“As a practicing ophthalmologist and scientific researcher, I have witnessed firsthand how RWD can transform clinical insights into meaningful advancements in patient care,” said Theodore Leng, MD, Professor of Ophthalmology and Director of Clinical and Translational Research, Byers Eye Institute at Stanford University School of Medicine. “Research-ready Qdata® from Verana Health provides deep insights into disease progression and treatment effectiveness.”